Diabetes mellitus arising in pregnancy. Diabetes mellitus in pregnancy, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Myoinositol supplementation powder the ino fulic commercial name containing 2000 mg of myoinositol and 200 µg of folic acid (manufactured by the company Lo.Li Pharm
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Conscious written consent Pregnant women with singleton pregnancy Age above 18 years old Gestational age 14 weeks Pr-pregnancy BMI>= 25 and less than 30 kg / m 2 Fasting glucose less than 92 mg / dL or Random glucose less than 200 mg / dL No chronic diseases such as diabetes, high blood pressure and cardiovascular disease Non-smoking and alcohol
Exclusion criteria
Exclusion criteria: The death experience of one of the first-degree relatives during pregnancy Treatment with corticosteroids during pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglyceride. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;Total cholesterol. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;LDL. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;HDL. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;Fasting blood sugar. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;Glucose tolerance test of 1 and 2 hours with 75 g of oral glucose. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;Fasting insulin. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal).;Insulin sensitivity. Timepoint: In the second trimester of the week( 24-28 ). Method of measurement: Testes based on laboratorial rutine( Detailed description in the proposal). | — |
Secondary
| Measure | Time frame |
|---|---|
| Neonatal and pregnancy outcomes. Timepoint: The end of pregnancy for the outcome of pregnancy and infancy. Method of measurement: Questionnaire and complete the checklist using patient file.;Side effect of drug. Timepoint: In the second trimester of pregnancy (week 24-28) and the third trimester of pregnancy (week 37_38). Method of measurement: Drug side effect Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMouloud Agajani Delavar
Babol University of Medical Sciences
Outcome results
None listed